Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS Trial)

Chest

Volumn 134, Issue 4, 2008, Pages 794-800

  Papaioannou, Alexandra ^a   Kennedy, Courtney C ^a   Freitag, Andreas ^a   Ioannidis, George ^a   O'Neill, John ^a   Webber, Colin ^b   Pui, Margaret ^c   Berthiaume, Yves ^d   Rabin, Harvey R ^e   Paterson, Nigel ^f   Jeanneret, Alphonse ^d   Matouk, Elias ^g   Villeneuve, Josee ^h   Nixon, Madeline ^a   Adachi, Jonathan D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c SCARBOROUGH HOSPITAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f WESTERN UNIVERSITY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h LAVAL UNIVERSITY   (Canada)

Author keywords

Alendronate; Cystic fibrosis; Low bone mass; Osteoporosis; Randomized controlled trial

Indexed keywords

ALENDRONIC ACID; CALCIUM; PLACEBO; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE OBSTRUCTION; KYPHOSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SEIZURE; STOMACH PAIN; VERTEBRA FRACTURE; VOMITING;

EID: 53949091546     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0608     Document Type: Article

References (31)

1. Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 2007; 28:279-288
2. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90:1888-1896
3. Boyle MP. Update on maintaining bone health in cystic fibrosis. Curr Opin Pulm Med 2006; 12:453-458
4. Hecker TM, Aris RM. Management of osteoporosis in adults with cystic fibrosis. Drugs 2004; 64:133-147
5. Papaioannou A, Parkinson W, Ferko N, et al. Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 2003; 14:913-917
6. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update; a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745-755
7. Yankaskas JR, Mallory GB Jr. Lung transplantation in cystic fibrosis: consensus conference statement. Chest 1998; 113:217-226
8. Haworth CS, Selby PL, Webb AK, et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004; 59:613-617
9. Shead EF, Haworth CS, Gunn E, et al. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:306-311
10. Lambrinoudaki I, Christodoulakos G, Botsis D. Bisphosphonates. Ann N Y Acad Sci 2006; 1092:397-402
11. Cawood TJ, McKenna MJ, Gallagher CG, et al. Oral bisphosphonates improve bone mineral density in adults with cystic fibrosis. Ir Med J 2005; 98:270-273
12. Conway SP, Oldroyd B, Morton A, et al. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax 2004; 59:699-703
13. Ringuier B, Leboucher B, Leblanc M, et al. Effect of oral biphosphonates in patients with cystic fibrosis and low bone mineral density. Arch Pediatr 2004; 11:1445-1449
14. Aris RM, Lester GE, Caminiti M, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004; 169:77-82
15. Ware J, Kosinski M, Dewey J. How to score version two of the SF-36 health survey. Lincoln, RI: QualityMetric Incorporated, 2000
16. Genant HK. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1995; 10:997-998
17. Genant HK, Li J, Wu CY, et al. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom 2000; 3:281-290
18. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey: Canadian Multicentre Osteoporosis Study Research Group. Can Med Assoc J 2000; 163:265-271
19. Qin L, Choy W, Au S, et al. Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis. J Orthop Surg 2007; 2:9
20. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20:141-151
21. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-1199
22. Bonnick S, Broy S, Kaiser F, et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 2007; 23:1341-1349
23. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146:416-424
24. Iwamoto J, Takeda T, Sato Y, et al. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol 2007; 26:161-167
25. Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005; 6:39
26. Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006; 17:716-723
27. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355:675-684
28. Haworth CS, Selby PL, Webb AK, et al. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998; 352:1753-1754
29. Haworth CS, Selby PL, Adams JE, et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56:314-316
30. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164:1108-1112
31. Shane E, Papadopoulos A, Staron RB, et al. Bone loss and fracture after lung transplantation. Transplantation 1999; 68:220-227